Pulmonary Large Cell Neuroendocrine Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PLM038 MIFTS: 29	Pulmonary Large Cell Neuroendocrine Carcinoma Categories: Cancer diseases, Neuronal diseases, Respiratory diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Pulmonary Large Cell Neuroendocrine Carcinoma

MalaCards integrated aliases for Pulmonary Large Cell Neuroendocrine Carcinoma:

Name: Pulmonary Large Cell Neuroendocrine Carcinoma ¹² ¹⁵

Large Cell Lung Neuroendocrine Carcinoma ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:6658

NCIt ⁴⁹ C5672 C6875

SNOMED-CT ⁶⁷ 128628002

UMLS ⁷¹ C1265996 C1334363

Sources

Summaries for Pulmonary Large Cell Neuroendocrine Carcinoma

MalaCards based summary : Pulmonary Large Cell Neuroendocrine Carcinoma, also known as large cell lung neuroendocrine carcinoma, is related to neuroendocrine carcinoma and neuroendocrine tumor, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Pulmonary Large Cell Neuroendocrine Carcinoma is SYP (Synaptophysin). The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and prostate.

Wikipedia : ⁷⁴ Large cell neuroendocrine carcinoma of the lung (LCNEC) is a highly malignant neoplasm arising from... more...

Sources

Related Diseases for Pulmonary Large Cell Neuroendocrine Carcinoma

Diseases related to Pulmonary Large Cell Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)

#	Related Disease	Score	Top Affiliating Genes
1	neuroendocrine carcinoma	31.2	SYP NCAM1 CHGA
2	neuroendocrine tumor	30.5	SYP NCAM1 CHGA
3	large cell neuroendocrine carcinoma	30.2	SYP NCAM1 KIF5B CHGA ALK
4	small cell cancer of the lung	30.1	SYP NCAM1 CHGA
5	small cell carcinoma	30.0	SYP NCAM1 CHGA ALK
6	large cell carcinoma	29.9	SYP STK11 NCAM1 CHGA
7	pulmonary neuroendocrine tumor	29.8	SYP NCAM1 CHGA
8	tubular adenocarcinoma	29.8	SYP NCAM1 CHGA
9	lung cancer susceptibility 3	28.7	STK11 NAPSA KIF5B ALK
10	breast neuroendocrine neoplasm	10.4	SYP CHGA
11	primary hepatic neuroendocrine carcinoma	10.4	SYP CHGA
12	small cell carcinoma of the bladder	10.4	SYP CHGA
13	acinar cell cystadenocarcinoma	10.4	SYP CHGA
14	vulvar eccrine porocarcinoma	10.3	SYP CHGA
15	cervical large cell neuroendocrine carcinoma	10.3	SYP CHGA
16	gastrointestinal neuroendocrine benign tumor	10.3	SYP CHGA
17	appendix carcinoid tumor	10.3	SYP CHGA
18	auditory system cancer	10.3	SYP CHGA
19	mixed ductal-endocrine carcinoma	10.3	SYP CHGA
20	cauda equina neoplasm	10.3	SYP CHGA
21	duodenal benign neoplasm	10.3	SYP CHGA
22	ampulla of vater neoplasm	10.3	SYP CHGA
23	breast papillary carcinoma	10.3	SYP CHGA
24	middle ear adenoma	10.3	SYP CHGA
25	carotid body cancer	10.3	SYP CHGA
26	gastric neuroendocrine neoplasm	10.3	SYP CHGA
27	pineocytoma	10.3	SYP CHGA
28	adenocarcinoma	10.3
29	appendix adenocarcinoma	10.3	SYP CHGA
30	pancreatic gastrinoma	10.3	SYP CHGA
31	gastrinoma	10.3	SYP CHGA
32	lung oat cell carcinoma	10.3	SYP CHGA
33	cervix small cell carcinoma	10.3	SYP CHGA
34	gastrointestinal neuroendocrine tumor	10.3	SYP CHGA
35	carcinoid tumors, intestinal	10.3	SYP CHGA
36	carcinoid syndrome	10.3	SYP CHGA
37	binswanger's disease	10.3	SYP CHGA
38	pancreatic acinar cell adenocarcinoma	10.3	SYP CHGA
39	olfactory neuroblastoma	10.3	SYP CHGA
40	extra-adrenal pheochromocytoma	10.3	SYP CHGA
41	sarcomatoid transitional cell carcinoma	10.3	SYP ALK
42	small intestine benign neoplasm	10.3	SYP CHGA
43	ganglioneuroblastoma	10.3	SYP ALK
44	granulosa cell tumor of the ovary	10.3	SYP CHGA
45	horseshoe kidney	10.3	SYP CHGA
46	peritoneal serous adenocarcinoma	10.3	SYP CHGA
47	clear cell meningioma	10.3	SYP CHGA
48	nodular ganglioneuroblastoma	10.3	CHGA ALK
49	adrenal medulla cancer	10.3	SYP CHGA
50	microcystic adenoma	10.3	SYP CHGA

Graphical network of the top 20 diseases related to Pulmonary Large Cell Neuroendocrine Carcinoma:

Sources

Symptoms & Phenotypes for Pulmonary Large Cell Neuroendocrine Carcinoma

UMLS symptoms related to Pulmonary Large Cell Neuroendocrine Carcinoma:

fever, dyspnea, hemoptysis, coughing

Sources

Drugs & Therapeutics for Pulmonary Large Cell Neuroendocrine Carcinoma

Drugs for Pulmonary Large Cell Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 7)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904 498142

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

Etoposide

Approved

Phase 2

33419-42-0

36462

Synonyms:

(−)-etoposide

(-)-Etoposide

121471-01-0

136598-18-0

201594-04-9

33419-42-0

35317-32-9

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside

4-Demethylepipodophyllotoxin b-D-ethylideneglucoside

4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside

4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside

4-demethylepipodophyllotoxin β-D-ethylideneglucoside

4-Demethylepipodophyllotoxin β-D-ethylideneglucoside

4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside

4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin

51854-34-3

76576-58-4

9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

AB00438905

AC1L1FN8

AC1L1VT3

AC1L6246

AC1NR4OG

AC1O4WGG

AC1O7M1N

AC1Q47JJ

alpha-D-Glucopyranosyl isomer etoposide

Ambap33419-42-0

Baxter brand OF etoposide

Baxter oncology brand OF etoposide

Bio1_000489

Bio1_000978

Bio1_001467

BPBio1_000673

BRD-K37798499-001-02-5

Bristol myers brand OF etoposide

Bristol myers squibb brand OF etoposide

Bristol-myers brand OF etoposide

Bristol-myers squibb brand OF etoposide

BSPBio_000611

C01576

CCRIS 2392

Celltop

CHEBI:4911

CHEBI:588795

CHEMBL44657

CID11758093

CID284997

CID3310

CID36462

CID5284558

CID6419930

CID6610299

CPD000112002

D00125

DB00773

DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,

Demethyl epipodophyllotoxin ethylidine glucoside

Demethyl Epipodophyllotoxin Ethylidine Glucoside

Demethyl-epiodophyllotoxin ethylidene glucoside

Demethylepipodophyllotoxin-beta-D-ethylideneglucoside

E0675

E1383_SIGMA

EINECS 251-509-1

Epipodophyllotoxin VP-16213

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

Eposide

Eposin

Eposin, Vepesid, VP-16, Toposar, Etoposide

eto GRY

eto-GRY

Etomedac

ETOP

Etopol

Etopophos

Etopophos (phosphate salt)

Etopos

etoposide

Etoposide

Etoposide (JP15/USP/INN)

Etoposide (VP16)

Etoposide [USAN:INN:BAN:JAN]

Etoposide pierre fabre

Etoposide teva

Etoposide, (5a alpha)-isomer

Etoposide, (5a alpha,9 alpha)-isomer

Etoposide, (5S)-isomer

Etoposide, alpha D glucopyranosyl isomer

Etoposide, alpha-D-glucopyranosyl isomer

Etoposido

Etoposido [INN-Spanish]

etoposido Ferrer farma

Etoposidum

Etoposidum [INN-Latin]

Etosid

Exitop

Ferrer brand OF etoposide

Gry brand OF etoposide

HMS1569O13

HMS2052N05

HMS2089F14

HSDB 6517

I06-0248

KBioSS_002410

Lastet

Lemery brand OF etoposide

LS-1214

Medac brand OF etoposide

MLS000049957

MLS001074951

MLS001424283

MLS002153463

MLS002207239

MLS002222184

MolPort-003-983-431

MolPort-004-905-001

MolPort-004-955-161

NCGC00025056-02

NChemBio.2007.10-comp19

nchembio.573-comp8

nchembio873-comp2

NK 171

Novartis brand OF etoposide

NSC 141540

NSC141540

NSC-141540

Onkoposid

Onkoworks brand OF etoposide

Pharmachemie brand OF etoposide

Pierre fabre brand OF etoposide

Prasfarma brand OF etoposide

Prestwick_211

Prestwick0_000396

Prestwick1_000396

Prestwick2_000396

Prestwick3_000396

Riboposid

Ribosepharm brand OF etoposide

S1225_Selleck

SAM001246880

Sanfer brand OF etoposide

SMR000112002

SPBio_002532

ST056353

Tedec meiji brand OF etoposide

Teva brand OF etoposide

Toposar

trans-Etoposide

UNII-6PLQ3CP4P3

Vepesid

VePesid

VePESID (TN)

Vepesid J

Vepeside

Vépéside sandoz

Vépéside-sandoz

VP 16

VP 16 (pharmaceutical)

VP 16213

VP 16-213

VP-16

VP-16-213

ZINC03830818

ZINC03938684

Zuyeyidal

Etoposide phosphate

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Tubulin Modulators

Phase 2

Antimitotic Agents

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study	Unknown status	NCT02943798	Phase 2	etoposide plus carboplatin;Paclitaxel plus carboplatin
2	Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017)	Completed	NCT03305133

Search NIH Clinical Center for Pulmonary Large Cell Neuroendocrine Carcinoma

Sources

Genetic Tests for Pulmonary Large Cell Neuroendocrine Carcinoma

Sources

Anatomical Context for Pulmonary Large Cell Neuroendocrine Carcinoma

MalaCards organs/tissues related to Pulmonary Large Cell Neuroendocrine Carcinoma:

⁴⁰

Lung, Brain, Prostate, Pituitary, Neutrophil, Bronchial Epithelium

Sources

Publications for Pulmonary Large Cell Neuroendocrine Carcinoma

Articles related to Pulmonary Large Cell Neuroendocrine Carcinoma:

(show top 50) (show all 88)

#	Title	Authors	PMID	Year
1	Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. ⁶¹	Takimoto Sato M...Kawai Y	32499913	2020
2	The role of postoperative radiotherapy (PORT) in pulmonary large cell neuroendocrine carcinoma (PLCNEC). ⁶¹	Gang Jin...Xiang Song	32156456	2020
3	The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis. ⁶¹	Cao L...Liu SX	32567658	2020
4	Pituitary Metastasis of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report. ⁶¹	Hu HP...Bowes D	32274284	2020
5	Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. ⁶¹	Shi M...Zhang J	32206552	2020
6	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. ⁶¹	Zhuo M...Zhao J	31694833	2020
7	Surgical treatment of a digital metastasis of a large cell lung neuroendocrine carcinoma: A rare secondary anatomical localization. ⁶¹	Berthier C...Lupon E	31870515	2020
8	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. ⁶¹	Zhang JT...Zhong WZ	31775086	2020
9	A Semiquantitative Scoring System May Allow Biopsy Diagnosis of Pulmonary Large Cell Neuroendocrine Carcinoma. ⁶¹	Baine MK...Homer RJ	31593583	2020
10	Bronchial intraepithelial recurrence of a pulmonary large cell neuroendocrine carcinoma. ⁶¹	Kojima H...Ohde Y	32086146	2020
11	DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. ⁶¹	Hermans BCM...Dingemans AMC	31678831	2019
12	Neuroendocrine marker staining pattern categorization of small-sized pulmonary large cell neuroendocrine carcinoma. ⁶¹	Minami K...Maniwa Y	31583856	2019
13	First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy. ⁶¹	McClelland S...Lautenschlaeger T	31516396	2019
14	Incidence of composite intestinal adenoma-microcarcinoid in 158 surgically resected polyps and its association with squamous morule. ⁶¹	Fu Z...Lee H	31326865	2019
15	Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. ⁶¹	Yang Q...Sun J	30734490	2019
16	Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). ⁶¹	Hermans BCM...PALGA-group	30885341	2019
17	Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? ⁶¹	Derks JL...Thunnissen E	30485478	2019
18	CD146 promotes migration and proliferation in pulmonary large cell neuroendocrine carcinoma cell lines. ⁶¹	Piao Y...Gao Y	30675274	2019
19	Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. ⁶¹	Zhao Y...Bowes D	30107896	2019
20	Prognostic significance of G6PD expression and localization in lung adenocarcinoma. ⁶¹	Nagashio R...Sato Y	29753088	2019
21	Stereotactic body radiation therapy for pulmonary large cell neuroendocrine carcinoma: a case report. ⁶¹	Jo IY...Yeo SG	30863102	2019
22	Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study. ⁶¹	Cao L...Liu YP	30944773	2019
23	Clinicopathological characteristics and prognosis of pulmonary large cell neuroendocrine carcinoma aged ≥65 years. ⁶¹	Cao L...Liu YP	31149394	2019
24	Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma. ⁶¹	He Y...Chen Y	31560723	2019
25	Double-edged role of radiotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. ⁶¹	Jiang Y...Shen H	31772675	2019
26	Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel KIF5B-ALK Fusion Oncokinase. ⁶¹	Shimizu N...Wakasa T	30591488	2019
27	Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report. ⁶¹	Wei J...Lu YF	30572435	2018
28	[Pulmonary Non-tuberculous Mycobacteriosis Complicated with Pulmonary Large Cell Neuroendocrine Carcinoma;Report of a Case]. ⁶¹	Nakashima S...Watanabe A	30185750	2018
29	Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration. ⁶¹	Inage T...Yoshino I	29271588	2018
30	Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? ⁶¹	Zhou F...Zhou C	29413048	2018
31	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. ⁶¹	Rekhtman N...Joubert P	28884744	2018
32	Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. ⁶¹	Derks JL...PALGA-Group	29066508	2018
33	Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. ⁶¹	Tang H...Wu Y	29765234	2018
34	Leptomeningeal metastasis of pulmonary large-cell neuroendocrine carcinoma: A case report and review of the literature. ⁶¹	Yang G...Liu S	28943940	2017
35	Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. ⁶¹	Kim KW...Choi YL	28204910	2017
36	Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? ⁶¹	Derks JL...PALGA group	28572122	2017
37	Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma. ⁶¹	Lou G...Song Z	28024928	2017
38	Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma. ⁶¹	Kasahara N...Takahashi T	28529747	2017
39	Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401). ⁶¹	Kawabe T...Hashimoto N	27903179	2016
40	Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma. ⁶¹	Makino T...Iyoda A	27368130	2016
41	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. ⁶¹	Rekhtman N...Ladanyi M	26960398	2016
42	Clinical features of large cell neuroendocrine carcinoma: a population-based overview. ⁶¹	Derks JL...Dingemans AM	26541538	2016
43	[Clinical Analysis of 22 Cases of Pulmonary Large Cell Neuroendocrine Cancer]. ⁶¹	Qian Z...Li B	26903161	2016
44	A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report. ⁶¹	Wang Y...Zhou J	26622712	2015
45	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. ⁶¹	Fasano M...Morgillo F	26039012	2015
46	Pulmonary large-cell neuroendocrine carcinoma presenting as multiple cutaneous metastases. ⁶¹	Mestre T...Cardoso J	26176530	2015
47	Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma. ⁶¹	Zhang XK...Zhang L	26060407	2015
48	Pulmonary large cell neuroendocrine carcinoma exhibiting extensive pagetoid spread in the bronchial epithelium: A case report. ⁶¹	Ogawa H...Maniwa Y	25364438	2014
49	Cutaneous metastasis from pulmonary large cell neuroendocrine carcinoma in the scalp. ⁶¹	Ishida M...Okabe H	24966991	2014
50	Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. ⁶¹	Odate S...Katano M	24023298	2013

Sources

Genes for Pulmonary Large Cell Neuroendocrine Carcinoma

Genes related to Pulmonary Large Cell Neuroendocrine Carcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SYP	Synaptophysin	Protein Coding	12.65	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	CHGA	Chromogranin A	Protein Coding	12.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	VGF	VGF Nerve Growth Factor Inducible	Protein Coding	11.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	10.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	KIF5B	Kinesin Family Member 5B	Protein Coding	10.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	LCN1	Lipocalin 1	Protein Coding	6.19	DISEASES inferred ¹⁵
7	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	6.03	DISEASES inferred ¹⁵
8	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	5.94	DISEASES inferred ¹⁵
9	STK11	Serine/Threonine Kinase 11	Protein Coding	5.93	DISEASES inferred ¹⁵

Sources

Variations for Pulmonary Large Cell Neuroendocrine Carcinoma

Sources

Expression for Pulmonary Large Cell Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Pulmonary Large Cell Neuroendocrine Carcinoma.

Sources

Pathways for Pulmonary Large Cell Neuroendocrine Carcinoma

Sources

GO Terms for Pulmonary Large Cell Neuroendocrine Carcinoma

Sources

Sources for Pulmonary Large Cell Neuroendocrine Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia